Peptides for Women Over 40: Addressing Age-Specific Hormonal Changes

The years after 40 bring a convergence of hormonal shifts that affect nearly every system in the body. Growth hormone production, which has been declining since your mid-20s, drops to levels that meaningfully impact metabolism, body composition, sleep quality, and tissue repair. Meanwhile, the perimenopause transition (which typically begins in the early to mid-40s) introduces fluctuating and eventually declining estrogen and progesterone levels that compound these effects.

The result is a set of interconnected changes that many women experience simultaneously: stubborn weight gain (especially around the midsection), disrupted sleep, thinning skin and hair, brain fog, joint stiffness, reduced libido, and slower recovery from exercise and injuries. These aren’t random. They’re driven by specific, measurable hormonal declines.

Peptide therapy doesn’t replace hormones. It’s not a substitute for hormone replacement therapy (HRT) where that’s appropriate. But several peptides target specific aspects of aging physiology that affect women over 40, and understanding which ones address which changes can help you make informed decisions with your provider.

This guide focuses on the why behind each peptide recommendation, connecting it to the specific age-related change it addresses. For general information about peptide therapy for women, see our broader guide.

Key takeaways

• Growth hormone secretagogues (sermorelin, ipamorelin) address the measurable GH decline that accelerates after 40, affecting metabolism, sleep, body composition, and recovery
• BPC-157 supports gut health and tissue repair, both areas where perimenopause creates new challenges
• GHK-Cu targets the collagen and elastin decline behind visible skin aging and hair thinning
• Semaglutide and tirzepatide address the metabolic resistance to weight loss that intensifies with hormonal changes after 40
• PT-141 works on the neurological basis of desire, targeting a specific aspect of sexual health that many women experience in perimenopause and menopause
• Peptides complement but do not replace HRT, nutrition, exercise, and sleep hygiene

Table of contents

1. What changes after 40, and why
2. Growth hormone decline: sermorelin and ipamorelin
3. Gut health and tissue repair: BPC-157
4. Skin, hair, and collagen: GHK-Cu
5. Metabolism and weight management: semaglutide and tirzepatide
6. Libido and sexual health: PT-141
7. Sleep and recovery
8. Cognitive function and brain fog
9. Safety considerations for women over 40
10. FAQ
11. Sources

What changes after 40, and why

Understanding the biology behind age-related changes helps explain why certain peptides may be relevant and others aren’t.

Growth hormone decline

Growth hormone (GH) production peaks during adolescence and begins declining at approximately 1-2% per year starting in the mid-20s [1]. By age 40, most women produce roughly half the GH they did at 20. By 50, levels may be 25-30% of peak.

This matters because GH isn’t just about growth. In adults, it regulates:

• GH promotes lean muscle maintenance and fat metabolism. Declining levels contribute to the shift toward higher body fat percentage and loss of muscle mass.
• GH is released primarily during deep (slow-wave) sleep. Low GH and poor sleep create a negative feedback loop: less deep sleep means less GH production, and less GH means lighter, more fragmented sleep.
• Skin, joints, muscles, and connective tissue all depend on GH-mediated repair processes. Slower recovery from exercise, more persistent joint aches, and thinner skin all correlate with GH decline.
• Basal metabolic rate decreases partly due to GH-related changes in body composition. Less muscle means fewer calories burned at rest.

The perimenopause transition

Perimenopause typically begins between ages 40-45 (sometimes earlier) and lasts 4-8 years before menopause. During this transition, estrogen and progesterone levels fluctuate unpredictably before their eventual decline [2].

The effects are wide-ranging:

• Hot flashes and night sweats (vasomotor symptoms)
• Increased anxiety, irritability, and depressive symptoms
• Fat shifts from hips and thighs to the abdomen, driven by changing estrogen levels
• Estrogen influences gut motility, microbiome composition, and intestinal permeability, so many women develop new GI symptoms during perimenopause
• Declining estrogen and testosterone affect both desire and physical arousal
• Brain fog, difficulty concentrating, and memory issues, since estrogen plays a significant role in neurotransmitter function
• Estrogen helps maintain cartilage and collagen, and its decline accelerates joint deterioration and skin aging

The compound effect

GH decline and perimenopause happening simultaneously creates a compound effect. Neither alone would be as disruptive, but together they create a cascade where multiple systems are affected at once. This is why many women experience a noticeable shift in their health trajectory after 40, rather than a gradual slide.

Growth hormone decline: sermorelin and ipamorelin

Growth hormone secretagogues don’t inject synthetic GH. They stimulate your pituitary gland to produce more of your own GH. This is an important distinction because it maintains the body’s feedback loops and produces a more physiological GH release pattern.

Sermorelin

Sermorelin is a 29-amino-acid peptide that mimics growth hormone-releasing hormone (GHRH). It’s been used clinically since the 1990s and has the longest track record of any GH secretagogue.

Sermorelin addresses the root cause of GH decline (reduced GHRH signaling from the hypothalamus) rather than replacing GH directly. For women over 40, the benefits reported in clinical practice include:

• Improved sleep quality, particularly deep sleep duration [3]
• Gradual improvement in body composition (reduced fat mass, preserved lean mass)
• Better exercise recovery
• Improved skin elasticity and hydration

Sermorelin for women has specific considerations around timing and dosing. See our dedicated guide for details.

Typical protocol: 200-300 μg subcutaneously at bedtime (to amplify the natural nighttime GH pulse). Cycles of 3-6 months are common, with periodic breaks.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that works through a different receptor (the ghrelin receptor) than sermorelin. It’s often preferred for its cleaner side effect profile. Unlike older GH secretagogues, ipamorelin doesn’t significantly raise cortisol or prolactin [4].

The selectivity is particularly relevant for women in perimenopause, who may already be dealing with cortisol dysregulation and hormonal sensitivity. Ipamorelin provides GH stimulation without adding to the hormonal noise.

The CJC-1295 and ipamorelin combination is among the most commonly prescribed peptide stacks for women over 40. CJC-1295 (a modified GHRH analog with a longer half-life) provides sustained GH elevation, while ipamorelin adds pulsatile GH release. Together, they produce a stronger and more sustained GH response than either alone. See our CJC-1295/Ipamorelin guide for details.

What to expect

GH secretagogues produce gradual effects. Most women report improved sleep within 2-4 weeks, with body composition and other changes developing over 2-3 months. They’re not dramatic. They’re restorative. The goal is to bring GH levels back toward a more youthful range, not to create supraphysiological levels.

Gut health and tissue repair: BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide originally isolated from human gastric juice. Its relevance for women over 40 is twofold: gut health and systemic tissue repair.

The gut connection

Perimenopause affects the gastrointestinal system more than many women expect. Estrogen receptors are present throughout the GI tract, and fluctuating estrogen levels during perimenopause can cause [5]:

• Increased intestinal permeability (“leaky gut”)
• Changes in gut microbiome composition
• New or worsening food sensitivities
• Bloating, changes in bowel habits
• Increased susceptibility to gastric irritation

BPC-157 has extensive preclinical data on gut mucosal protection and repair. It promotes mucosal healing, reduces inflammatory markers in the GI tract, and has shown protective effects against NSAID-induced gastric damage [6]. For women who develop new GI issues during perimenopause (which is common), BPC-157 addresses a specific, identifiable need.

For more detail, see our BPC-157 for gut health guide.

Tissue repair beyond the gut

BPC-157’s tissue repair effects extend to muscles, tendons, and connective tissue. As estrogen declines, so does the body’s baseline capacity for tissue repair. Women over 40 often notice that injuries take longer to heal, exercise recovery is slower, and minor strains that would have resolved in days now linger for weeks.

BPC-157’s ability to promote angiogenesis, fibroblast activity, and collagen synthesis [7] addresses this repair deficit. It’s not replacing estrogen, but it may partially compensate for the reduced repair capacity that comes with estrogen decline.

Practical considerations

BPC-157 is one of the few peptides with evidence for oral stability. For women primarily seeking gut benefits, oral BPC-157 capsules may be appropriate. For systemic tissue repair, subcutaneous injection is generally preferred.

Typical dose: 250-500 μg daily, either orally (for gut focus) or subcutaneously (for systemic effects). Cycles of 4-8 weeks.

Skin, hair, and collagen: GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that declines significantly with age. Levels at 60 are roughly 40% of what they were at 20 [8]. This decline directly correlates with visible aging changes.

Why skin changes accelerate after 40

Collagen production declines by approximately 1% per year starting in the mid-20s, but the rate accelerates significantly during perimenopause. Studies show women lose approximately 30% of their skin collagen in the first five years after menopause [9]. Estrogen directly stimulates collagen synthesis, so its decline has an outsized effect on skin.

The results are visible: thinner skin, reduced elasticity, deeper wrinkles, slower wound healing, and increased dryness. Hair also thins due to reduced collagen at the hair follicle and altered growth cycles.

How GHK-Cu addresses this

GHK-Cu stimulates production of collagen types I, III, and V, along with elastin and decorin [8]. It works at the gene expression level, upregulating genes involved in tissue repair and remodeling while suppressing pro-inflammatory genes. Specifically:

• GHK-Cu increases collagen production in fibroblasts, directly addressing the age-related decline
• Elastin gives skin its bounce-back quality, and GHK-Cu stimulates elastin synthesis
• Chronic low-grade inflammation (inflammaging) accelerates skin aging. GHK-Cu suppresses inflammatory interleukins.
• GHK-Cu supports superoxide dismutase (SOD) activity, reducing oxidative damage to skin cells

For hair specifically, GHK-Cu’s effects on the hair follicle environment (increased collagen, improved blood supply, reduced inflammation) support healthier growth cycles. Our GHK-Cu for hair guide covers this in detail.

Application options

GHK-Cu is available both topically and as a subcutaneous injection:

• Topical application is effective for localized skin concerns, applied directly to face, neck, or areas of concern. It is widely used in medical-grade skincare.
• Injectable use at 1-2 mg daily subcutaneously provides systemic collagen support, addressing skin, hair, joints, and connective tissue simultaneously.
• Cycles of 4-8 weeks are typical for injectable protocols. Topical use can be ongoing.

For women over 40, the injectable form offers broader benefits because it supports collagen throughout the body, not just where it’s applied topically. This matters because the collagen decline affects joints, tendons, blood vessels, and internal tissues, not just visible skin.

For a full overview, see our anti-aging peptides guide.

Metabolism and weight management: semaglutide and tirzepatide

Weight management becomes measurably harder after 40 for biological reasons that have nothing to do with willpower. The metabolic shift is driven by declining GH (less lean mass, lower metabolic rate), changing estrogen levels (abdominal fat redistribution), and insulin resistance that increases with age.

Why it’s harder after 40

Several factors converge:

• Women lose approximately 3-5% of muscle mass per decade after 30, accelerating after menopause. Less muscle means fewer calories burned at rest.
• Estrogen helps maintain insulin sensitivity. As it declines, cells become less responsive to insulin, promoting fat storage, particularly visceral (abdominal) fat.
• Perimenopause often involves cortisol dysregulation, which promotes abdominal fat deposition and makes weight loss more difficult.
• Poor sleep (from night sweats, insomnia) impairs appetite regulation hormones (leptin and ghrelin), increasing hunger and cravings.

How semaglutide works

Semaglutide is a GLP-1 receptor agonist that reduces appetite through central nervous system effects on satiety centers. It slows gastric emptying, reduces food reward signaling, and improves insulin sensitivity [10]. Clinical trials demonstrated average weight loss of 15-17% of body weight over 68 weeks.

For women over 40, semaglutide addresses the metabolic resistance that makes conventional diet and exercise less effective than it was at 30. It’s not overriding biology. It’s compensating for altered appetite and metabolic signaling.

Tirzepatide: the dual-action option

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss efficacy than semaglutide in head-to-head trials. The SURMOUNT-1 trial demonstrated average weight loss of up to 22.5% over 72 weeks [14].

The dual mechanism matters for women over 40: GIP (glucose-dependent insulinotropic polypeptide) works synergistically with GLP-1 to improve insulin sensitivity and glucose metabolism. For women dealing with worsening insulin resistance from estrogen decline, this dual action may address the metabolic problem more completely than GLP-1 alone.

Important considerations

Both semaglutide and tirzepatide are prescription medications with well-documented side effects, primarily gastrointestinal (nausea, which typically diminishes over time). They require medical supervision and aren’t appropriate for everyone. Women considering these medications should discuss them with their provider in the context of their overall hormonal and metabolic picture.

For more detail, see our peptides for weight loss guide and our semaglutide vs. tirzepatide guide.

Typical doses:

• Semaglutide starts at 0.25 mg weekly, titrated up to 1.0-2.4 mg weekly based on response and tolerance
• Tirzepatide starts at 2.5 mg weekly, titrated up to 5-15 mg weekly based on response

Libido and sexual health: PT-141

Declining libido during and after perimenopause is extremely common. Studies suggest 40-55% of women experience decreased sexual desire during this transition [11]. The causes are multifactorial: declining estrogen and testosterone, changes in body image, fatigue, vaginal dryness, and stress. But there’s also a neurological component that’s often overlooked. For a broader look at peptide options for sexual health in both men and women, see our guide on peptides for libido.

How PT-141 is different

PT-141 (bremelanotide, brand name Vyleesi) works through a fundamentally different mechanism than any hormone or supplement. It’s a melanocortin receptor agonist that acts in the central nervous system, directly activating the neural pathways involved in sexual desire [12].

This distinction matters. Most approaches to low libido focus on hormones (estrogen, testosterone) or blood flow. PT-141 works on desire itself, targeting the brain’s motivation and arousal signaling. It’s the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, with demonstrated improvements in desire, arousal, and orgasm scores versus placebo [12].

Relevance for women over 40

The neurological component of desire can decline independently of hormone levels. Some women on adequate HRT still experience low libido because the hormone replacement doesn’t fully restore central nervous system arousal signaling. PT-141 targets this specific gap.

PT-141 was originally discovered accidentally during research on tanning peptides (melanocortin peptides). Researchers noticed unexpected effects on sexual arousal in study participants. This serendipitous discovery led to focused development and eventual FDA approval.

Practical use

PT-141 is used on an as-needed basis, not daily:

• 1.75 mg subcutaneously, approximately 45 minutes before anticipated sexual activity
• Not recommended more than once in 24 hours or more than 8 doses per month
• Common side effects include nausea (most common, usually mild), flushing, and headache
• May cause transient increases in blood pressure

For detailed information, see our PT-141 for women guide and PT-141 side effects guide.

Sleep and recovery

Sleep disruption is one of the most impactful changes after 40. It’s driven by declining GH, fluctuating estrogen (night sweats), altered cortisol rhythms, and reduced melatonin production. Poor sleep then worsens virtually every other age-related change: it impairs metabolism, increases inflammation, reduces cognitive function, and slows recovery.

Peptide approaches to sleep

Growth hormone secretagogues (sermorelin, ipamorelin) are the most commonly used peptides for sleep in women over 40. GH is released primarily during deep slow-wave sleep, and GH secretagogues administered at bedtime amplify this natural release. The result is deeper, more restorative sleep, which then improves GH production in a positive feedback loop [3].

BPC-157 may support sleep indirectly through its effects on the dopaminergic and serotonergic systems, which influence sleep-wake regulation [6]. Some practitioners report improved sleep quality in patients using BPC-157, though this isn’t its primary indication.

For a deeper look at peptide approaches to sleep, see our peptides for sleep guide.

Recovery

The combination of declining GH, reduced estrogen, and disrupted sleep significantly impairs recovery from exercise, illness, and injury. Women over 40 often find that the exercise routine they maintained for years now leaves them more sore and fatigued.

Addressing recovery involves GH secretagogues for the systemic repair deficit, BPC-157 for tissue-level repair support, and adequate sleep as the foundation. Peptides can help with recovery, but sleep hygiene matters too.

Cognitive function and brain fog

Brain fog (difficulty concentrating, word-finding problems, feeling mentally “slow”) is one of the most frustrating perimenopause symptoms. Estrogen plays a significant role in acetylcholine production, cerebral blood flow, and synaptic plasticity, so its fluctuation during perimenopause directly affects cognitive function [13].

What peptides can offer

The peptide most relevant to cognitive support is GHK-Cu, which has neuroprotective properties through its anti-inflammatory and antioxidant effects. It reduces neuroinflammation (which increases during perimenopause) and supports brain-derived neurotrophic factor (BDNF) pathways [8].

Growth hormone secretagogues also contribute to cognitive function. GH and IGF-1 are involved in neuroplasticity and cerebral blood flow. Restoring more youthful GH levels may support the cognitive capacity that declines with GH deficiency [1].

It’s important to be realistic: peptides are not nootropics in the traditional sense, and brain fog during perimenopause is primarily driven by estrogen fluctuations. If brain fog is a primary concern, discussing HRT with your provider is important. Peptides may support cognitive function but don’t replace estrogen’s specific role in the brain.

Safety considerations for women over 40

Cancer screening

Several peptides promote cell growth, angiogenesis, or growth hormone production. Women over 40 should be current on mammograms, Pap smears, and other age-appropriate cancer screenings before starting any peptide that promotes cell proliferation. This includes BPC-157, TB-500, and GH secretagogues. Most peptide providers require current screening results.

Hormone interactions

If you’re on HRT (estrogen, progesterone, testosterone), discuss peptide therapy with both your hormone provider and peptide provider. There are no known direct interactions, but the effects are complementary and dosing adjustments may be warranted.

Thyroid considerations

Thyroid function changes during perimenopause, and GH secretagogues can affect thyroid hormone metabolism. Women with thyroid conditions should have their thyroid levels monitored more closely while using GH-stimulating peptides.

Bone density

Declining estrogen accelerates bone loss. GH secretagogues may support bone density through their effects on osteoblast activity and IGF-1, but they don’t replace the need for calcium, vitamin D, weight-bearing exercise, and potentially bone-specific medications if indicated.

For general safety information, see our peptide safety guide.

FAQ

What are the best peptides for women over 40?▼

The “best” peptide depends on your primary concerns. For body composition and sleep: sermorelin or CJC-1295/ipamorelin. For gut health and healing: BPC-157. For skin and hair: GHK-Cu. For weight management: semaglutide. For libido: PT-141. Many women over 40 benefit from a combination approach, starting with a GH secretagogue as the foundation and adding targeted peptides based on specific symptoms.

How are peptides different from hormone replacement therapy?▼

HRT replaces specific hormones (estrogen, progesterone, testosterone) to levels the body no longer produces. Peptides work differently: they stimulate the body’s own production (GH secretagogues), support tissue repair (BPC-157), or target specific receptors (PT-141). They’re complementary, not competing approaches. Some women use both HRT and peptides, addressing hormonal decline with HRT and functional decline with peptides.

Are peptides safe during perimenopause?▼

The peptides discussed in this guide have generally favorable safety profiles. However, perimenopause involves unique considerations: hormonal sensitivity, increased cancer screening importance, and potential interactions with HRT. Work with a provider who understands both peptide therapy and menopausal medicine. Always be current on age-appropriate cancer screenings before starting growth-promoting peptides.

Can peptides help with hot flashes and night sweats?▼

Peptides don’t directly address vasomotor symptoms (hot flashes, night sweats), which are primarily driven by estrogen fluctuations. HRT is the most effective treatment for these symptoms. However, improved sleep quality from GH secretagogues may help women cope better with sleep disruption caused by night sweats, even without directly reducing them.

How long does it take to see results from peptides?▼

Timeline varies by peptide and concern. Sleep improvements from GH secretagogues are often noticed within 2-4 weeks. Body composition changes develop over 2-3 months. Skin improvements from GHK-Cu become visible at 4-8 weeks, while semaglutide typically shows meaningful weight changes within 3-4 months. PT-141 works within 45 minutes of each dose. The changes are restorative, not dramatic, so patience is important.

Do I need a prescription for these peptides?▼

Most peptides require a prescription from a licensed medical provider. Semaglutide and PT-141 (Vyleesi) are FDA-approved medications with established prescription pathways. Other peptides like BPC-157, sermorelin, and GHK-Cu are prescribed as compounded medications through peptide clinics. See our guide on how to get peptides prescribed for details.

Sources

1. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991;73(5):1081-1088. doi:10.1210/jcem-73-5-1081

2. Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44(3):497-515. doi:10.1016/j.ecl.2015.05.001

3. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/S0026-0495(97)90175-7

4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

5. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45-53. doi:10.1016/j.maturitas.2017.06.025

6. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119

7. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1033-1042. doi:10.2174/13816128113199990421

8. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987

9. Brincat M, Moniz CJ, Studd JW, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol. 1985;92(3):256-259. doi:10.1111/j.1471-0528.1985.tb01091.x

10. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

11. Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause. 2009;16(3):442-452. doi:10.1097/gme.0b013e3181948dd0

12. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs. 2015;29(11):915-933. doi:10.1007/s40263-015-0288-1

13. Maki PM, Henderson VW. Cognition and the menopause transition. Menopause. 2016;23(7):803-805. doi:10.1097/GME.0000000000000681

14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038